Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report

From Decision Resources

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Flomax, also marketed as Astellas's Harnal in Japan, is the physician's drug of choice for newly diagnosed benign prostatic hyperplasia patients. Garnering more patient share than any other alpha blocker in first- and second-line therapy for benign prostatic hyperplasia, Flomax holds a 55.2 percent first-line patient share, compared with 12.4 percent for Sanofi-Aventis's Uroxatral, 4.8 percent for doxazosin (Pfizer's Cardura/Cardura XL, generics), and 4.3 percent for terazosin (Abbott's Hytrin, generics).

"Flomax stands out among alpha blockers thanks to its lower propensity to induce orthostatic hypotension, despite evidence of a high incidence of retrograde ejaculation and higher cost relative to generic agents in this class", said Nathan Calloway, analyst at Decision Resources. "However, rather than calling attention to Flomax's side-effect/safety profile, the highest proportion of urologists we surveyed (83 percent) rank familiarity with the drug as an important reason to choose Flomax over Uroxatral, whereas the largest percentage of primary care physicians (66 percent) believe that Flomax's reimbursement and formulary position is a key advantage over Uroxatral's."

The report entitled Treatment Algorithms in Benign Prostatic Hyperplasia also finds that slightly less than one-fifth (18.9 percent) of newly diagnosed benign prostatic hyperplasia patients receive pharmacological treatment within one year of their initial diagnosis. Primary care physicians and urologists surveyed suggest that patient reluctance to take drugs that are associated with sid
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and NEW ORLEANS , May 22, ... field of regenerative medicine, presented new data generated in ... Group (a leading health economics consultancy) demonstrating the significant ... (DFU) and venous leg ulcers (VLU) place upon the ... this research, which reveal annual costs of up to ...
(Date:5/22/2013)... N.Y. , May 22, 2013  Cleveland BioLabs, Inc. ... present at the Second Annual Marcum LLP Microcap Conference, May ... Neil Lyons , CPA, Chief ... and biodefense programs on May 30 at 1:30 p.m. Eastern ... will be available on the Investors page of the Cleveland ...
(Date:5/22/2013)... Mold remediation could take a toll on one's ... way to cut down the process' expense. And so, to ... details of a method how to kill mold ... prevented, My Cleaning Products said. But in case mold gets ... remediation must then be promptly implemented as it poses several ...
(Date:5/22/2013)... Alton Housing Authority was hit by bed bugs. A ... their presence has already caused the company $35,000 for treatment. ... spending, My Cleaning Products shared a way how to ... the report that to clear the infestation , the ... employees also attended a mandatory training on bed bugs, it ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2
... , MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - YM BioSciences ... life sciences product development company that identifies and advances ... stages of development, today reported additional results from a ... diffuse intrinsic pontine glioma (DIPG). The updates to the ...
... , - Influenza: 50/50 joint venture agreement signed ... and pandemic flu, manufacturing facility, ... - Thrombolytic: Nears licensing and sales of KINLYTIC(TM) thrombolytic, ... 25% of the dairy semen collection centres now under, ...
... Reportlinker.com announces that a new ... its catalogue. , Worldwide ... Electron Microscope Market Shares, Strategies, and ... , http://www.reportlinker.com/p0153912/Worldwide-Optical-Transmission-TEM-and-Scanning-SEM-Electron-Microscope-Market-Shares-Strategies-and-Forecasts-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ...
Cached Biology Technology:YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 4Microbix Biosystems Provides a Corporate Update 2Microbix Biosystems Provides a Corporate Update 3Microbix Biosystems Provides a Corporate Update 4Microbix Biosystems Provides a Corporate Update 5Microbix Biosystems Provides a Corporate Update 6Microbix Biosystems Provides a Corporate Update 7Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 2Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 3Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 4Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 5
(Date:5/22/2013)... pneumophila bacteria is responsible for legionellosis, an infectious ... infect us, this pathogen has developed a complex method ... our cells, thus avoiding these acting against the infectious ... centre, CIC bioGUNE, in which teams from the National ... National Supercomputation Centre in Barcelona (BSC) have also participated, ...
(Date:5/22/2013)... screening for prostate cancer could become as easy for ... to UC Irvine research published today in the ... more than a decade of work, UC Irvine chemists ... markers for prostate cancer in urine, meaning that the ... and at dramatically lower cost. The same technology could ...
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2
... Information System will provide valuable information for assessing environmental ... Environmental Health Sciences (NIEHS), one of the National Institutes ... up-to-date data to public health and safety workers on ... well as demographic information for local populations. ...
... million from the Grand Challenges in Global health initiative ... to humans to aid in testing the safety and ... & Melinda Gates Foundation, the Yale project will be ... Chair of Immunobiology at Yale University School of Medicine, ...
... A new website with a Global Information System will ... Hurricane Katrina. The National Institute of Environmental Health Sciences ... the website to provide the most up-to-date data to ... waters, infrastructure and industry maps, as well as demographic ...
Cached Biology News:FDA approves child-friendly AIDS medicine 2Grand Challenges in Global Health initiative funds Yale project 2NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina 2
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
anti-achaete...
... Oct6 ( Abpromise for all tested applications). ... to KLH derived from within residues 1 - ... acid sequence is proprietary) (Peptide ... Entrez Gene ID: 5453 ...
Biology Products: